<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Zibb.com: Serono SA (Industry News &amp; Blogs)</title><link>http://www.zibb.com/all/theme/cq/Serono+SA</link><atom:link rel="self" type="application/rss+xml" href="http://www.zibb.com/all/theme/cq/Serono+SA" /><description>
					Zibb. The Global business search engine.
				</description><language>
					en-US
				</language><webMaster>search@zibb.com (RB Search)</webMaster><copyright>Copyright (c) 2007 Reed Business Information. All rights reserved.</copyright><pubDate>Wed, 23 Jul 2008 08:10:46 GMT</pubDate><lastBuildDate>Wed, 23 Jul 2008 08:10:46 GMT</lastBuildDate><ttl>60</ttl><image><title>Zibb.com: Serono SA (Industry News &amp; Blogs)
          </title><width>88</width><height>31</height><link>http://www.zibb.com/all/theme/cq/Serono+SA</link><url>
						http://www.zibb.com/images/en/g_zibb_logo_beta.gif
					</url></image><item><title>Merck KGaA Earnings Fall Short on Liquid Crystals (Update2) - Blo...
      </title><link>http://www.bloomberg.com/apps/news?pid=20601087&amp;sid=a.v_qnutrf5Q&amp;refer=home</link><description>July 23 (Bloomberg) -- Merck KGaA, the German maker of the Erbitux cancer drug, reported second-quarter profit that fell short of analyst estimates as sales of materials used for flat- panel televisions were hurt by the stronger euro. Merck shares dropped as much as 4.</description><guid>http://www.bloomberg.com/apps/news?pid=20601087&amp;sid=a.v_qnutrf5Q&amp;refer=home</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate>Wed, 23 Jul 2008 08:10:46 GMT</pubDate><source url="http://www.bloomberg.com" /></item><item><title>Germany's Merck posts 1st-quarter profit as revenue rises 8 perce...
      </title><link>http://www.iht.com/articles/ap/2008/04/23/business/EU-FIN-EARNS-Germany-Merck.php</link><description>BERLIN: German drug maker Merck KGaA said Wednesday it had swung to a net profit in the first quarter on an 8.3 percent rise in revenue, contrasting with a loss a year earlier that was caused by costs from the acquisition of Swiss biotechnology company Serono.</description><guid>http://www.iht.com/articles/ap/2008/04/23/business/EU-FIN-EARNS-Germany-Merck.php</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate>Wed, 23 Apr 2008 08:54:56 GMT</pubDate><source url="http://www.iht.com" /></item><item><title>Merck Serono introduces Cyanokit in Japan</title><link>http://www.pharmaceutical-business-review.com/article_news.asp?guid=DB2834D6-2F06-447B-95E2-17CE74E32381</link><description>Merck Serono, a division of Merck KGaA of Darmstadt, Germany, has announced that Cyanokit is commercially available in Japan as of March 18, 2008, through its local affiliate Merck Serono Corporation Limited.</description><guid>http://www.pharmaceutical-business-review.com/article_news.asp?guid=DB2834D6-2F06-447B-95E2-17CE74E32381</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate>Thu, 20 Mar 2008 11:14:00 GMT</pubDate><source url="http://www.pharmaceutical-business-review.com" /></item><item><title>Packaging Today - Merck KGaA announces acquisition of Serono</title><link>http://www.packagingtoday.co.uk/story.asp?storycode=43270</link><description>Subject to antitrust review and closing of the purchase, Merck holds 64.5% of the capital of Serono and 75.5% of the voting rights, for which Merck agreed to pay CHF 1,100 per share in cash. Merck will make a public tender offer under Swiss law for the same price of CHF 1,100 per share.</description><guid>http://www.packagingtoday.co.uk/story.asp?storycode=43270</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate /><source url="http://www.packagingtoday.co.uk" /></item><item><title>Germany's Merck 4Q profit soars on Serono deal, divestment of gen...
      </title><link>http://www.iht.com/articles/ap/2008/02/18/business/EU-FIN-EARNS-Germany-Merck.php</link><description>Germany's Merck 4Q profit soars to nearly €3.4B on Serono deal, divestment of generics unit</description><guid>http://www.iht.com/articles/ap/2008/02/18/business/EU-FIN-EARNS-Germany-Merck.php</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate>Mon, 18 Feb 2008 10:08:31 GMT</pubDate><source url="http://www.iht.com" /></item><item><title>Biolex signs Merck for antibody optimization</title><link>http://www.pharmaceutical-business-review.com/article_news.asp?guid=86F5C255-4C82-434B-8FAA-710D7F8670AD</link><description>Biolex Therapeutics has entered into an agreement with Merck KGaA, acting for its division for innovative pharmaceuticals Merck Serono, to evaluate antibody optimization and production in Biolexs proprietary Lex System.</description><guid>http://www.pharmaceutical-business-review.com/article_news.asp?guid=86F5C255-4C82-434B-8FAA-710D7F8670AD</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate>Wed, 20 Feb 2008 14:52:00 GMT</pubDate><source url="http://www.pharmaceutical-business-review.com" /></item><item><title>Merck KGaA Profit Surges on Gain From Generics Sale (Update1) - B...
      </title><link>http://www.bloomberg.com/apps/news?pid=20601087&amp;sid=avmEFjmGozHU&amp;refer=home</link><description>Feb. 18 (Bloomberg) -- Merck KGaA, the world's biggest maker of liquid crystals, reported profit that missed analysts' estimates because of lower sales of chemicals used in flat- panel screens and costs from the purchase of Swiss biotechnology company Serono SA.</description><guid>http://www.bloomberg.com/apps/news?pid=20601087&amp;sid=avmEFjmGozHU&amp;refer=home</guid><category domain="http://www.zibb.com">Serono SA</category><pubDate>Mon, 18 Feb 2008 06:51:59 GMT</pubDate><source url="http://www.bloomberg.com" /></item></channel></rss>